Industry Feature

Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Sarah Shizuko Morimoto, PsyD

Digital therapeutics are a rapidly developing type of treatment option across several therapeutic areas, including mental health. And while the technology is advancing rapidly, the science behind it needs time to catch up, so it’s important to evaluate the supporting evidence when considering digital therapeutics for mental health.1 Joining Dr. Charles Turck to share her insights on how we can assess digital therapeutics is Dr. Sarah Shizuko Morimoto, Associate Professor of Population Health Sciences at the University of Utah in Salt Lake City.

Reference:

1. American Psychiatric Association. Accessed July 3, 2024. https://www.psychiatry.org/psychiatrists/practice/mental-health-apps/the-app-evaluation-model

Dr. Morimoto is a paid consultant of Otsuka.

November 2024 US.UNB.X.24.00100

Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Steven Maron, MD, MSc

Given the recent identification of actionable biomarkers like PD-L1 and MSI-H,1-3 it’s important to test patients with gastroesophageal cancer for these biomarkers as they may provide insights into options for a patient’s treatment plan.4,5 To learn more about how we can detect biomarkers and other key considerations for biomarker screening in gastroesophageal cancer, Dr. Charles Turck speaks with Dr. Steven Maron, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center in New York.

References:

1. The Cancer Genome Atlas Network. Nature. 2014;513:202-209.
2. Fontana E, et al. Ther Adv Med Oncol. 2016;8:113-125.
3. Yang B, et al. J Exp Clin Cancer Res. 2019;38:283.
4. American Cancer Society. https://www.fightcancer.org/sites/default/files/Improving%20Access%20to%20Biomarker%20Testing_FINAL.pdf. Accessed July 20, 2024.
5. Catenacci DVT, et al. Future Oncol. 2019;15:2073-2082.

©2024 Amgen Inc. All rights reserved. USA-OCF-82400 9/24

Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Robert McCarron, MD

Guest: Arwen Podesta, MD

Digital therapeutics are a relatively new and intriguing treatment option in mental health care but translating them from a clinical trial to clinical practice can be challenging. That’s why Drs. Robert McCarron and Arwen Podesta join Dr. Charles Turck to share strategies for incorporating digital therapeutics into clinical practice. Dr. McCarron is a Professor in the Department of Psychiatry and Human Behavior at the University of California, Irvine School of Medicine, and Dr. Podesta is the President of the Louisiana Psychiatric Medical Association.

Drs. McCarron and Podesta are consultants for Otsuka.

September 2024 US.UNB.X.24.00073

Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Maggie Emerson, DNP, APRN, PMHNP-BC

Guiding patients and caregivers through the fast-moving landscape of digital therapeutics can be a challenging but worthwhile part of providing effective and accessible care. That’s why Dr. Charles Turck speaks with Dr. Maggie Emerson about partnering with patients and caregivers around this relatively new treatment in mental health care. Dr. Emerson is a Clinical Associate Professor at the University of Nebraska Medical Center College of Nursing in Omaha.

Dr. Emerson is a paid consultant of Otsuka.

September 2024 US.UNB.X.24.00082

Guest: Jennifer L. Payne, MD

Guest: Melissa Simon, MD

Since postpartum depression is a serious medical condition that can negatively impact mothers, infants, and partners, it is important to identify symptoms in a timely manner.1-4 Dr. Jennifer Payne and Dr. Melissa Simon are here to share their clinical experiences screening patients for postpartum depression, explore strategies to overcome common challenges in screening, and identify best practices for collaborating in the care of perinatal women.

Dr. Payne is a Professor of Psychiatry and Neurobehavioral Sciences as well as Obstetrics and Gynecology at the University of Virginia, and Dr. Simon is a Professor of Obstetrics and Gynecology at the Northwestern University Feinberg School of Medicine.

References

1. American Psychiatric Association. Depressive disorders. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5™. 5th ed. American Psychiatric Publishing; 2013:155-188.
2. Campbell SB, Cohn JF, Meyers T. Depression in First-Time Mothers: Mother-Infant Interaction and Depression Chronicity. Dev Psychol. 1995;31:349-357.
3. Moore Simas TA, Huang MY, Patton C, et al. The humanistic burden of postpartum depression: a systematic literature review. Curr Med Res Opin. 2019;35(3):383-393.
4. Thompson KS, Fox JE. Post-partum depression: a comprehensive approach to evaluation and treatment. Ment Health Fam Med. 2010;7(4):249-257.

Sage Therapeutics and the Sage Therapeutics logo …

Host: Matt Birnholz, MD

Guest: Jennifer L. Payne, MD

Guest: Melissa Simon, MD

Postpartum depression is a serious medical condition that is among the most common complications during and after pregnancy; however, it is often underdiagnosed.1-4 To learn more about screening patients for postpartum depression, Dr. Matt Birnholz speaks with Dr. Jennifer Payne and Dr. Melissa Simon about screening strategies, the impact of health inequities, and the latest medical guidelines regarding the importance of early screening for postpartum depression.

Dr. Payne is a Professor of Psychiatry and Neurobehavioral Sciences as well as Obstetrics and Gynecology at the University of Virginia, and Dr. Simon is a Professor of Obstetrics and Gynecology at the Northwestern University Feinberg School of Medicine.

References

1. American Psychiatric Association. Depressive disorders. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5™. 5th ed. American Psychiatric Publishing; 2013:155-188.
2. Bauman BL, Ko JY, Cox S, et al. Vital Signs: Postpartum Depressive Symptoms and Provider Discussions About Perinatal Depression - United States, 2018. MMWR Morb Mortal Wkly Rep. 2020;69(19):575-581.
3. Cox EQ, Sowa NA, Meltzer-Brody SE, Gaynes BN. The Perinatal Depression Treatment Cascade: Baby Steps Toward Improving Outcomes. J Clin Psychiatry. 2016;77(9):1189-1200.
4. Thompson KS, Fox JE. Post-partum depression: a comprehensive approach to evaluation and treatment. Ment Health Fam Med. 2010;7(4):249-257.
…

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA

Guest: Leigh Anne Cantrell, MD, MSPH

The updated ASCCP guidelines now address the use of dual-stain technology for cervical cancer management. CINtec PLUS Cytology is a test for the co-expression of p16 and Ki67 and confirms the presence of a transforming HPV infection and defines patients with high-risk cervical disease. To learn more about these guidelines and how to apply them in practice, join Dr. Leigh Cantrell, Medical Physician and Fellow in the American College of Obstetrics and Gynecology.

COBAS and CINTEC are trademarks of Roche.
All other product names and trademarks are the property of their respective owners. 07/24

Guest: TJ Gan, MD, MBA, MHS, FRCA (UK), FRCA (lre), LicAc

Guest: Dru Riddle, PhD, DNP, CRNA

When it comes to postoperative nausea and vomiting (PONV) management, multimodal, antiemetic therapy based on patients’ risk factors is routinely provided to minimize the incidence, but unfortunately, patients may still develop breakthrough PONV, in which an antiemetic should be administered from a different class from what's given for prevention.1 Barhemsys® (amisulpride) is an FDA-approved antiemetic for the treatment of PONV in patients who have or have not received prophylaxis.2 Learn more about this treatment option along with current management guidelines, key clinical considerations, and a real-world case study with TJ Gan, MD, MBA, MHS, and Dru Riddle, PhD, DNP. Dr. Gan is the Head of the Division of Anesthesiology and Perioperative Medicine, Critical Care, and Pain Medicine at the University of Texas MD Anderson Cancer Center in Houston, and Dr. Riddle is a certified nurse anesthetist at Texas Christian University in Ft. Worth, TX.

Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Jamie Koprivnikar, MD

Patients with lower-risk myelodysplastic syndromes (MDS) lack treatment options, specifically in treating anemia. However, the FDA approval of Reblozyl (luspatercept-aamt) as a first-line therapy for treating anemia in ESA-naïve patients with lower-risk MDS presents an option for this patient population. Tune in to learn more about evaluating patients with MDS, the potential of Reblozyl, and where it fits into the treatment landscape with Dr. Charles Turck as he takes a deep dive with Dr. Jamie Koprivnikar, MD, Hematologist, Oncologist, at Hackensack Meridian Health.

REBLOZYL® is a trademark of Celgene Corporation, a Bristol Myers Squibb company.
REBLOZYL® is licensed from Merck & Co. Inc., Rahway, NJ, USA and its affiliates.
© 2024 Bristol-Myers Squibb Company
2007-US-2300376 03/24

Host: Andrew Wilner, MD, FACP, FAAN

Guest: Victoria Leavitt, PhD

Disease-modifying therapies (DMTs) are an effective option for patients with multiple sclerosis (MS). In fact, a recent study presented at the 2023 joint ECTRIMS-ACTRIMS meeting in Italy found that MS patients being treated with a DMT had better cognitive function than those who were not. However, the same study also found that women are less likely than men to receive DMT treatment. Dive further into the findings with Dr. Andrew Wilner and Dr. Victoria Leavitt, Assistant Professor of Neuropsychology at Columbia University.